APO Research
Talk to an analyst

APO RESEARCH · REPORT

Combination Vaccine and Multivalent Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Combination Vaccine and Multivalent Vaccine Industry Growth and Trends Forecast to 2032

27 December 2025123 pages

Choose your research edition.

Industry ResearchCombination Vaccine and Multivalent Vaccine Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Combination Vaccine and Multivalent Vaccine Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Combination Vaccine and Multivalent Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Combination Vaccine and Multivalent Vaccine Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Combination Vaccine and Multivalent Vaccine Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

According to APO Research, the global Combination Vaccine and Multivalent Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Combination Vaccine and Multivalent Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Combination Vaccine and Multivalent Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Combination Vaccine and Multivalent Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Combination Vaccine and Multivalent Vaccine market include BioNTech, Dynavax, Moderna, Novavax, Pfizer, Sanofi Pasteur, AIM Bio, Beijing Institute of Biological Products and Chengdu Institute of Biological Products, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Combination Vaccine and Multivalent Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Combination Vaccine and Multivalent Vaccine market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Combination Vaccine and Multivalent Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Combination Vaccine and Multivalent Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Combination Vaccine and Multivalent Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Combination Vaccine and Multivalent Vaccine Market by Company

BioNTech

Dynavax

Moderna

Novavax

Pfizer

Sanofi Pasteur

AIM Bio

Beijing Institute of Biological Products

Chengdu Institute of Biological Products

Antejin Biotechnology

GlaxoSmithKline

Kangtai Bio

Sinovac

Lanzhou Institute of Biological Products

Minhai Biological

Merck & Co.

Wanbangde Pharmaceutical

Wantai Biological

Walvax

Wuhan Institute of Biological Products

Zhifei Biological

Sino Biopharm

Combination Vaccine and Multivalent Vaccine Segment by Type

Combination Vaccine

Multivalent Vaccine

Combination Vaccine and Multivalent Vaccine Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Combination Vaccine and Multivalent Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Combination Vaccine and Multivalent Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Combination Vaccine and Multivalent Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Combination Vaccine and Multivalent Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Combination Vaccine and Multivalent Vaccine companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Combination Vaccine and Multivalent Vaccine Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Combination Vaccine and Multivalent Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Combination Vaccine and Multivalent Vaccine Market Share by Region (2021-2026) Table 4. Global Combination Vaccine and Multivalent Vaccine Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Combination Vaccine and Multivalent Vaccine Market Share by Region (2027-2032) Table 6. Global Combination Vaccine and Multivalent Vaccine Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Combination Vaccine and Multivalent Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Combination Vaccine and Multivalent Vaccine Market Size Share by Type (2021-2026) Table 9. Global Combination Vaccine and Multivalent Vaccine Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Combination Vaccine and Multivalent Vaccine Market Size Share Forecasted by Type (2027-2032) Table 11. North America Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Combination Vaccine and Multivalent Vaccine Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Combination Vaccine and Multivalent Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Combination Vaccine and Multivalent Vaccine Market Size Share by Application (2021-2026) Table 24. Global Combination Vaccine and Multivalent Vaccine Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Combination Vaccine and Multivalent Vaccine Market Size Share Forecasted by Application (2027-2032) Table 26. North America Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Combination Vaccine and Multivalent Vaccine Industry Trends Table 37. Combination Vaccine and Multivalent Vaccine Industry Drivers Table 38. Combination Vaccine and Multivalent Vaccine Industry Opportunities and Challenges Table 39. Combination Vaccine and Multivalent Vaccine Industry Restraints Table 40. Global Combination Vaccine and Multivalent Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Company (2021-2026) Table 42. Global Combination Vaccine and Multivalent Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Combination Vaccine and Multivalent Vaccine Key Company Headquarters & Area Served Table 44. Global Combination Vaccine and Multivalent Vaccine Company, Product Type & Application Table 45. Global Combination Vaccine and Multivalent Vaccine Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Combination Vaccine and Multivalent Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. BioNTech Company Information Table 49. BioNTech Business Overview Table 50. BioNTech Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. BioNTech Combination Vaccine and Multivalent Vaccine Product Portfolio Table 52. BioNTech Recent Development Table 53. Dynavax Company Information Table 54. Dynavax Business Overview Table 55. Dynavax Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Dynavax Combination Vaccine and Multivalent Vaccine Product Portfolio Table 57. Dynavax Recent Development Table 58. Moderna Company Information Table 59. Moderna Business Overview Table 60. Moderna Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Moderna Combination Vaccine and Multivalent Vaccine Product Portfolio Table 62. Moderna Recent Development Table 63. Novavax Company Information Table 64. Novavax Business Overview Table 65. Novavax Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Novavax Combination Vaccine and Multivalent Vaccine Product Portfolio Table 67. Novavax Recent Development Table 68. Pfizer Company Information Table 69. Pfizer Business Overview Table 70. Pfizer Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Pfizer Combination Vaccine and Multivalent Vaccine Product Portfolio Table 72. Pfizer Recent Development Table 73. Sanofi Pasteur Company Information Table 74. Sanofi Pasteur Business Overview Table 75. Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Product Portfolio Table 77. Sanofi Pasteur Recent Development Table 78. AIM Bio Company Information Table 79. AIM Bio Business Overview Table 80. AIM Bio Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. AIM Bio Combination Vaccine and Multivalent Vaccine Product Portfolio Table 82. AIM Bio Recent Development Table 83. Beijing Institute of Biological Products Company Information Table 84. Beijing Institute of Biological Products Business Overview Table 85. Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio Table 87. Beijing Institute of Biological Products Recent Development Table 88. Chengdu Institute of Biological Products Company Information Table 89. Chengdu Institute of Biological Products Business Overview Table 90. Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio Table 92. Chengdu Institute of Biological Products Recent Development Table 93. Antejin Biotechnology Company Information Table 94. Antejin Biotechnology Business Overview Table 95. Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Product Portfolio Table 97. Antejin Biotechnology Recent Development Table 98. GlaxoSmithKline Company Information Table 99. GlaxoSmithKline Business Overview Table 100. GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Product Portfolio Table 102. GlaxoSmithKline Recent Development Table 103. Kangtai Bio Company Information Table 104. Kangtai Bio Business Overview Table 105. Kangtai Bio Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Kangtai Bio Combination Vaccine and Multivalent Vaccine Product Portfolio Table 107. Kangtai Bio Recent Development Table 108. Sinovac Company Information Table 109. Sinovac Business Overview Table 110. Sinovac Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Sinovac Combination Vaccine and Multivalent Vaccine Product Portfolio Table 112. Sinovac Recent Development Table 113. Lanzhou Institute of Biological Products Company Information Table 114. Lanzhou Institute of Biological Products Business Overview Table 115. Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio Table 117. Lanzhou Institute of Biological Products Recent Development Table 118. Minhai Biological Company Information Table 119. Minhai Biological Business Overview Table 120. Minhai Biological Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Minhai Biological Combination Vaccine and Multivalent Vaccine Product Portfolio Table 122. Minhai Biological Recent Development Table 123. Merck & Co. Company Information Table 124. Merck & Co. Business Overview Table 125. Merck & Co. Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Merck & Co. Combination Vaccine and Multivalent Vaccine Product Portfolio Table 127. Merck & Co. Recent Development Table 128. Wanbangde Pharmaceutical Company Information Table 129. Wanbangde Pharmaceutical Business Overview Table 130. Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Product Portfolio Table 132. Wanbangde Pharmaceutical Recent Development Table 133. Wantai Biological Company Information Table 134. Wantai Biological Business Overview Table 135. Wantai Biological Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Wantai Biological Combination Vaccine and Multivalent Vaccine Product Portfolio Table 137. Wantai Biological Recent Development Table 138. Walvax Company Information Table 139. Walvax Business Overview Table 140. Walvax Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Walvax Combination Vaccine and Multivalent Vaccine Product Portfolio Table 142. Walvax Recent Development Table 143. Wuhan Institute of Biological Products Company Information Table 144. Wuhan Institute of Biological Products Business Overview Table 145. Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio Table 147. Wuhan Institute of Biological Products Recent Development Table 148. Zhifei Biological Company Information Table 149. Zhifei Biological Business Overview Table 150. Zhifei Biological Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 151. Zhifei Biological Combination Vaccine and Multivalent Vaccine Product Portfolio Table 152. Zhifei Biological Recent Development Table 153. Sino Biopharm Company Information Table 154. Sino Biopharm Business Overview Table 155. Sino Biopharm Combination Vaccine and Multivalent Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 156. Sino Biopharm Combination Vaccine and Multivalent Vaccine Product Portfolio Table 157. Sino Biopharm Recent Development Table 158. North America Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. North America Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 160. North America Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2026) Table 161. North America Combination Vaccine and Multivalent Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. North America Combination Vaccine and Multivalent Vaccine Market Share Forecast by Country (2027-2032) Table 163. Europe Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Europe Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 165. Europe Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2026) Table 166. Europe Combination Vaccine and Multivalent Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Europe Combination Vaccine and Multivalent Vaccine Market Share Forecast by Country (2027-2032) Table 168. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 170. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2026) Table 171. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Share Forecast by Country (2027-2032) Table 173. Latin America Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Latin America Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 175. Latin America Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2026) Table 176. Latin America Combination Vaccine and Multivalent Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Latin America Combination Vaccine and Multivalent Vaccine Market Share Forecast by Country (2027-2032) Table 178. Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 180. Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2026) Table 181. Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Share Forecast by Country (2027-2032) Table 183. Research Programs/Design for This Report Table 184. Authors List of This Report Table 185. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Combination Vaccine and Multivalent Vaccine Product Image Figure 3. Global Combination Vaccine and Multivalent Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Combination Vaccine and Multivalent Vaccine Market Size (2021-2032) & (US$ Million) Figure 5. Global Combination Vaccine and Multivalent Vaccine Market Share by Region: 2025 VS 2032 Figure 6. Global Combination Vaccine and Multivalent Vaccine Market Share by Region (2021-2032) Figure 7. North America Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Combination Vaccine Image Figure 13. Global Combination Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Multivalent Vaccine Image Figure 15. Global Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Combination Vaccine and Multivalent Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Combination Vaccine and Multivalent Vaccine Market Share by Type 2025 VS 2032 Figure 18. North America Combination Vaccine and Multivalent Vaccine Market Size Share by Type (2021-2032) Figure 19. Europe Combination Vaccine and Multivalent Vaccine Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size Share by Type (2021-2032) Figure 21. Latin America Combination Vaccine and Multivalent Vaccine Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Combination Vaccine and Multivalent Vaccine Market Size Share by Type (2021-2032) Figure 23. Hospital Image Figure 24. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Centers for Disease Control and Prevention Image Figure 26. Global Centers for Disease Control and Prevention Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Others Image Figure 28. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Global Combination Vaccine and Multivalent Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Combination Vaccine and Multivalent Vaccine Market Share by Application 2025 VS 2032 Figure 31. North America Combination Vaccine and Multivalent Vaccine Market Size Share by Application (2021-2032) Figure 32. Europe Combination Vaccine and Multivalent Vaccine Market Size Share by Application (2021-2032) Figure 33. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size Share by Application (2021-2032) Figure 34. Latin America Combination Vaccine and Multivalent Vaccine Market Size Share by Application (2021-2032) Figure 35. Middle East and Africa Combination Vaccine and Multivalent Vaccine Market Size Share by Application (2021-2032) Figure 36. Global Top 5 and 10 Combination Vaccine and Multivalent Vaccine Players Market Share by Revenue in 2025 Figure 37. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 38. North America Combination Vaccine and Multivalent Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 39. North America Combination Vaccine and Multivalent Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 40. North America Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2032) Figure 41. Europe Combination Vaccine and Multivalent Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. Europe Combination Vaccine and Multivalent Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2032) Figure 44. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2032) Figure 47. Latin America Combination Vaccine and Multivalent Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Latin America Combination Vaccine and Multivalent Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Latin America Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2032) Figure 50. Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2032) Figure 53. Years Considered Figure 54. Research Process Figure 55. Key Executives Interviewed

Scope & coverage.

Types
  • Combination Vaccine
  • Multivalent Vaccine
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • BioNTech
  • Dynavax
  • Moderna
  • Novavax
  • Pfizer
  • Sanofi Pasteur
  • AIM Bio
  • Beijing Institute of Biological Products
  • Chengdu Institute of Biological Products
  • Antejin Biotechnology
  • GlaxoSmithKline
  • Kangtai Bio
  • Sinovac
  • Lanzhou Institute of Biological Products
  • Minhai Biological
  • Merck & Co.
  • Wanbangde Pharmaceutical
  • Wantai Biological
  • Walvax
  • Wuhan Institute of Biological Products
  • Zhifei Biological
  • Sino Biopharm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Combination Vaccine and Multivalent Vaccine Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Combination Vaccine and Multivalent Vaccine Market Size by Region (2021-2032)
  5. 1.4.1 Global Combination Vaccine and Multivalent Vaccine Market Size by Region (2021-2026)
  6. 1.4.2 Global Combination Vaccine and Multivalent Vaccine Market Size by Region (2027-2032)
  7. 1.5 Key Regions Combination Vaccine and Multivalent Vaccine Market Size (2021-2032)
  8. 1.5.1 North America Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (2021-2032)
2 Combination Vaccine and Multivalent Vaccine Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Combination Vaccine
  3. 2.1.2 Multivalent Vaccine
  4. 2.2 Global Combination Vaccine and Multivalent Vaccine Market Size by Type
  5. 2.2.1 Global Combination Vaccine and Multivalent Vaccine Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Combination Vaccine and Multivalent Vaccine Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Combination Vaccine and Multivalent Vaccine Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Combination Vaccine and Multivalent Vaccine Market Size by Regions
  9. 2.3.1 North America Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Type (2021-2026)
3 Combination Vaccine and Multivalent Vaccine Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital
  3. 3.1.2 Centers for Disease Control and Prevention
  4. 3.1.3 Others
  5. 3.2 Global Combination Vaccine and Multivalent Vaccine Market Size by Application
  6. 3.2.1 Global Combination Vaccine and Multivalent Vaccine Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Combination Vaccine and Multivalent Vaccine Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Combination Vaccine and Multivalent Vaccine Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Combination Vaccine and Multivalent Vaccine Market Size by Regions
  10. 3.3.1 North America Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Combination Vaccine and Multivalent Vaccine Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Combination Vaccine and Multivalent Vaccine Industry Trends
  2. 4.2 Combination Vaccine and Multivalent Vaccine Industry Drivers
  3. 4.3 Combination Vaccine and Multivalent Vaccine Industry Opportunities and Challenges
  4. 4.4 Combination Vaccine and Multivalent Vaccine Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Combination Vaccine and Multivalent Vaccine Revenue (2021-2026)
  2. 5.2 Global Combination Vaccine and Multivalent Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Combination Vaccine and Multivalent Vaccine Key Company Headquarters & Area Served
  4. 5.4 Global Combination Vaccine and Multivalent Vaccine Company, Product Type & Application
  5. 5.5 Global Combination Vaccine and Multivalent Vaccine Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Combination Vaccine and Multivalent Vaccine Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Combination Vaccine and Multivalent Vaccine Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Combination Vaccine and Multivalent Vaccine Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 BioNTech
  2. 6.1.1 BioNTech Company Information
  3. 6.1.2 BioNTech Business Overview
  4. 6.1.3 BioNTech Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 BioNTech Combination Vaccine and Multivalent Vaccine Product Portfolio
  6. 6.1.5 BioNTech Recent Developments
  7. 6.2 Dynavax
  8. 6.2.1 Dynavax Company Information
  9. 6.2.2 Dynavax Business Overview
  10. 6.2.3 Dynavax Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Dynavax Combination Vaccine and Multivalent Vaccine Product Portfolio
  12. 6.2.5 Dynavax Recent Developments
  13. 6.3 Moderna
  14. 6.3.1 Moderna Company Information
  15. 6.3.2 Moderna Business Overview
  16. 6.3.3 Moderna Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Moderna Combination Vaccine and Multivalent Vaccine Product Portfolio
  18. 6.3.5 Moderna Recent Developments
  19. 6.4 Novavax
  20. 6.4.1 Novavax Company Information
  21. 6.4.2 Novavax Business Overview
  22. 6.4.3 Novavax Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Novavax Combination Vaccine and Multivalent Vaccine Product Portfolio
  24. 6.4.5 Novavax Recent Developments
  25. 6.5 Pfizer
  26. 6.5.1 Pfizer Company Information
  27. 6.5.2 Pfizer Business Overview
  28. 6.5.3 Pfizer Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Pfizer Combination Vaccine and Multivalent Vaccine Product Portfolio
  30. 6.5.5 Pfizer Recent Developments
  31. 6.6 Sanofi Pasteur
  32. 6.6.1 Sanofi Pasteur Company Information
  33. 6.6.2 Sanofi Pasteur Business Overview
  34. 6.6.3 Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Product Portfolio
  36. 6.6.5 Sanofi Pasteur Recent Developments
  37. 6.7 AIM Bio
  38. 6.7.1 AIM Bio Company Information
  39. 6.7.2 AIM Bio Business Overview
  40. 6.7.3 AIM Bio Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 AIM Bio Combination Vaccine and Multivalent Vaccine Product Portfolio
  42. 6.7.5 AIM Bio Recent Developments
  43. 6.8 Beijing Institute of Biological Products
  44. 6.8.1 Beijing Institute of Biological Products Company Information
  45. 6.8.2 Beijing Institute of Biological Products Business Overview
  46. 6.8.3 Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
  48. 6.8.5 Beijing Institute of Biological Products Recent Developments
  49. 6.9 Chengdu Institute of Biological Products
  50. 6.9.1 Chengdu Institute of Biological Products Company Information
  51. 6.9.2 Chengdu Institute of Biological Products Business Overview
  52. 6.9.3 Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
  54. 6.9.5 Chengdu Institute of Biological Products Recent Developments
  55. 6.10 Antejin Biotechnology
  56. 6.10.1 Antejin Biotechnology Company Information
  57. 6.10.2 Antejin Biotechnology Business Overview
  58. 6.10.3 Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Product Portfolio
  60. 6.10.5 Antejin Biotechnology Recent Developments
  61. 6.11 GlaxoSmithKline
  62. 6.11.1 GlaxoSmithKline Company Information
  63. 6.11.2 GlaxoSmithKline Business Overview
  64. 6.11.3 GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Product Portfolio
  66. 6.11.5 GlaxoSmithKline Recent Developments
  67. 6.12 Kangtai Bio
  68. 6.12.1 Kangtai Bio Company Information
  69. 6.12.2 Kangtai Bio Business Overview
  70. 6.12.3 Kangtai Bio Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Kangtai Bio Combination Vaccine and Multivalent Vaccine Product Portfolio
  72. 6.12.5 Kangtai Bio Recent Developments
  73. 6.13 Sinovac
  74. 6.13.1 Sinovac Company Information
  75. 6.13.2 Sinovac Business Overview
  76. 6.13.3 Sinovac Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Sinovac Combination Vaccine and Multivalent Vaccine Product Portfolio
  78. 6.13.5 Sinovac Recent Developments
  79. 6.14 Lanzhou Institute of Biological Products
  80. 6.14.1 Lanzhou Institute of Biological Products Company Information
  81. 6.14.2 Lanzhou Institute of Biological Products Business Overview
  82. 6.14.3 Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
  84. 6.14.5 Lanzhou Institute of Biological Products Recent Developments
  85. 6.15 Minhai Biological
  86. 6.15.1 Minhai Biological Company Information
  87. 6.15.2 Minhai Biological Business Overview
  88. 6.15.3 Minhai Biological Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Minhai Biological Combination Vaccine and Multivalent Vaccine Product Portfolio
  90. 6.15.5 Minhai Biological Recent Developments
  91. 6.16 Merck & Co.
  92. 6.16.1 Merck & Co. Company Information
  93. 6.16.2 Merck & Co. Business Overview
  94. 6.16.3 Merck & Co. Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Merck & Co. Combination Vaccine and Multivalent Vaccine Product Portfolio
  96. 6.16.5 Merck & Co. Recent Developments
  97. 6.17 Wanbangde Pharmaceutical
  98. 6.17.1 Wanbangde Pharmaceutical Company Information
  99. 6.17.2 Wanbangde Pharmaceutical Business Overview
  100. 6.17.3 Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Product Portfolio
  102. 6.17.5 Wanbangde Pharmaceutical Recent Developments
  103. 6.18 Wantai Biological
  104. 6.18.1 Wantai Biological Company Information
  105. 6.18.2 Wantai Biological Business Overview
  106. 6.18.3 Wantai Biological Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Wantai Biological Combination Vaccine and Multivalent Vaccine Product Portfolio
  108. 6.18.5 Wantai Biological Recent Developments
  109. 6.19 Walvax
  110. 6.19.1 Walvax Company Information
  111. 6.19.2 Walvax Business Overview
  112. 6.19.3 Walvax Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Walvax Combination Vaccine and Multivalent Vaccine Product Portfolio
  114. 6.19.5 Walvax Recent Developments
  115. 6.20 Wuhan Institute of Biological Products
  116. 6.20.1 Wuhan Institute of Biological Products Company Information
  117. 6.20.2 Wuhan Institute of Biological Products Business Overview
  118. 6.20.3 Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
  120. 6.20.5 Wuhan Institute of Biological Products Recent Developments
  121. 6.21 Zhifei Biological
  122. 6.21.1 Zhifei Biological Company Information
  123. 6.21.2 Zhifei Biological Business Overview
  124. 6.21.3 Zhifei Biological Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  125. 6.21.4 Zhifei Biological Combination Vaccine and Multivalent Vaccine Product Portfolio
  126. 6.21.5 Zhifei Biological Recent Developments
  127. 6.22 Sino Biopharm
  128. 6.22.1 Sino Biopharm Company Information
  129. 6.22.2 Sino Biopharm Business Overview
  130. 6.22.3 Sino Biopharm Combination Vaccine and Multivalent Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  131. 6.22.4 Sino Biopharm Combination Vaccine and Multivalent Vaccine Product Portfolio
  132. 6.22.5 Sino Biopharm Recent Developments
7 North America
  1. 7.1 North America Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026)
  3. 7.3 North America Combination Vaccine and Multivalent Vaccine Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026)
  3. 8.3 Europe Combination Vaccine and Multivalent Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026)
  3. 10.3 South America Combination Vaccine and Multivalent Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst